Month: February 2025

Board of Trustees Initiates Review of Strategic Alternatives to Maximize Shareholder Value BETHESDA, Md., Feb. 13, 2025 (GLOBE NEWSWIRE) — Elme Communities (the “Company” or “Elme”) (NYSE: ELME), a multifamily REIT with communities in the Washington, DC metro area and the Atlanta metro area, reported financial and operating results today for the quarter and year ended December 31, 2024: Fourth Quarter Financial and Operational HighlightsNet loss was $3.0 million, or $0.03 per diluted share Core FFO was $20.7 million, or $0.24 per diluted share Same-store multifamily NOI increased by 1.7% compared to the prior year quarter Average Effective Monthly Rent Per Home increased 1.9% compared to the prior year quarter for our Same-Store Portfolio Effective blended Lease Rate Growth was 1.3% for our Same-Store Portfolio during the quarter,...

Atlanta, Feb. 13, 2025 (GLOBE NEWSWIRE) — Piedmont Office Realty Trust, Inc. (“Piedmont” or the “Company”) (NYSE:PDM), an owner of Class A office properties located primarily in major U.S. Sunbelt markets, today announced its results for the quarter and year ended December 31, 2024. Highlights for the Three Months and Year Ended December 31, 2024: Financial Results:  Three Months Ended   Year Ended(in 000s other than per share amounts ) December 31, 2024 December 31, 2023   December 31, 2024 December 31, 2023Net loss applicable to Piedmont $ (29,978 ) $ (28,030 )   $ (79,069 ) $ (48,387 )Net loss per share applicable to common stockholders – basic and diluted $ (0.24 ) $ (0.23 )   $ (0.64 ) $ (0.39 )Impairment charges $ 15,400   $ 18,489     $ 33,832   $ 29,446  Executive separation...

Raises 2025 Revenue Guidance Midpoint to $6.45 Billion; Reaffirms 2025 Adjusted EBITDA Guidance of $900 Million to $1.0 Billion BOSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) — DraftKings Inc. (Nasdaq: DKNG) (“DraftKings” or the “Company”) today announced its fourth quarter and fiscal year 2024 financial results. The Company also posted a letter to shareholders and an earnings presentation on the Investor Relations section of its website at investors.draftkings.com. Fourth Quarter 2024 HighlightsFor the three months ended December 31, 2024, DraftKings reported revenue of $1,393 million, an increase of $162 million, or 13%, compared to $1,231 million during the same period in 2023. The increase in the Company’s fourth quarter 2024 revenue was driven primarily by continued healthy customer engagement, efficient acquisition of new customers,...

TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) — Trisura Group Ltd. (“Trisura” or “Trisura Group”) (TSX: TSU), a leading specialty insurance provider, today announced financial results for the fourth quarter and year ended December 31, 2024. David Clare, President and CEO of Trisura, stated, “Trisura achieved strong Operating net income of $38.2 million in the quarter, or $0.79 per share, supporting our highest ever annual Operating net income of $135.8 million, driven by growth, strong underwriting, and higher Net investment income. Operating combined ratio of 81.5% for the quarter and 82.9% for the year shows the strength and potential of the combined platform. Growth, strong earnings, unrealized gains and the impact of foreign exchange lifted book value by 27% to $785 million, an all-time high. Profitability from core operations continued,...

Fiscal Q2 Revenue up 14% to $19.1 Million Achieves GAAP Profitability and Positive Cash Flow from Operations RANCHO CUCAMONGA, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) — iPower Inc. (Nasdaq: IPW) (“iPower” or the “Company”), a tech and data-driven ecommerce services provider and online retailer, today announced its financial results for the fiscal second quarter ended December 31, 2024. Fiscal Q2 2025 Results vs. Year-Ago QuarterTotal revenue increased 14% to $19.1 million. Gross profit increased 15% to $8.4 million, with gross margin up 40 bps to 44.0%. Net income attributable to iPower improved to $0.2 million or $0.01 per share, compared to net loss attributable to iPower of $1.9 million or $(0.06) per share. As of December 31, 2024, total debt was reduced by 31% to $4.4 million compared to $6.3 million as of June 30, 2024.Management...

MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter resultsRevenue of $39.2 million, a 33% decrease compared with $58.4 million in the prior-year period. Instrument revenue of $15.3 million compared with $35.1 million in the prior-year period. Instrument revenue in the fourth quarter of 2024 included 23 Revio® sequencing systems and 7 Vega™ sequencing systems. Consumables revenue of $18.8 million compared with $18.9 million in the prior-year period. Service and other revenue of $5.1 million compared with $4.4 million in the prior-year period.Gross margin, operating expenses, net income (loss), and net income (loss) per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are...

Revenue $7.17 billion, up 7 percent year over year GAAP gross margin 48.8 percent and non-GAAP gross margin 48.9 percent GAAP operating margin 30.4 percent and non-GAAP operating margin 30.6 percent GAAP EPS $1.45 and non-GAAP EPS $2.38, down 40 percent and up 12 percent year over year, respectively Generated $925 million in cash from operations and distributed $1.64 billion to shareholders including $1.32 billion in share repurchases and $326 million in dividendsSANTA CLARA, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) — Applied Materials, Inc. (NASDAQ: AMAT) today reported results for its first quarter ended Jan. 26, 2025. “The industry drive to accelerate the development of advanced compute and more sophisticated AI is gaining momentum,” said Gary Dickerson, President and CEO. “Applied Materials is enabling the major device architecture...

Strategic investments and partnerships set stage for strong second half outlook Reduced revolver debt by 31%, strengthening balance sheet and liquidity position Higher-margin Direct to Consumer sales reach 42% of gross revenue PLANTATION, Fla., Feb. 13, 2025 (GLOBE NEWSWIRE) — Alliance Entertainment Holding Corporation (Nasdaq: AENT), a global distributor and wholesaler specializing in music, movies, video games, electronics, arcades, and collectibles, reported its financial and operational results for the second quarter and six months ended December 31, 2024. Second Quarter FY 2025 and Subsequent HighlightsCompleted the acquisition of Handmade by Robots, a rapidly growing collectible brand known for its unique vinyl figures designed to replicate the look of hand-knit plush toys. This strategic acquisition bolsters Alliance...

VALENCIA, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights and Recent Business UpdatesCommercial revenue of $18.4 million, an increase of approximately 30% compared to the same period in 2023 Gross profit margin of 87.6% On December 19, 2024, the FDA granted 510(k) clearance for Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix On December 23, 2024, the FDA approved RECELL GO® mini On February 13, 2025, amended the credit agreement with OrbiMed, adjusting the trailing 12-month revenue covenants for upcoming quarters starting from March 31, 2025, through...

2024 Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of $410 million and Dojolvi® revenue of $88 million 2025 Financial Guidance: Total Revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million NOVATO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter and full year ended December 31, 2024 and shared financial guidance for 2025. “We have created a next-generation rare disease company on a pathway to profitability with meaningful revenue growth from multiple global products and a series of potential...